Results 41 to 50 of about 23,157 (220)

Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT)

European Journal of Medical Research, 2009
Objectives To assess the efficacy and safety of a treatment switch from a twice-daily (BID) regimen containing zidovudine (ZDV) and lamivudine (3TC) plus a third agent to a once daily (QD) regimen containing the fixed-dose combination of tenofovir DF ...
Arasteh K, Weitner L, Fenske S, Kuhlmann B, Freiwald M, Ebrahimi R, Gallo L, Ranneberg B, Mertenskoetter T   +8 more
doaj   +1 more source

Coronary Microcirculatory Dysfunction in People With HIV and Its Association With Antiretroviral Therapy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background HIV infection and abacavir‐containing antiretroviral regimens are associated with vascular endothelial dysfunction and increased cardiovascular risk. Positron emission tomography (PET)‐derived myocardial blood flow reserve (MBFR), the ratio of
Daniel M. Huck, Brittany Weber, Sean Parks, Sanjay Divakaran, Jenifer M. Brown, Courtney F. Bibbo, Leanne Barrett, Jon Hainer, Camden Bay, Laurel Martell, Laura Kogelman, Virginia A. Triant, Jacqueline Chu, Nina H. Lin, Kathleen Melbourne, Paul E. Sax, Marcelo F. Di Carli   +16 more
doaj   +1 more source

Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial

Clinical Infectious Diseases
Background Doravirine/islatravir is an investigational regimen that is being studied for human immunodeficiency virus type 1 (HIV-1) treatment. Methods In this phase 3, double-blind, double-dummy trial (ClinicalTrials.gov NCT04233879), previously ...
J. Rockstroh, R. Paredes, P. Cahn, Jean-Michel Molina, S. Sokhela, F. Hinestrosa, S. Kassim, Douglas Cunningham, J. Ghosn, J. Bogner, H. Gatanaga, Ernest Asante-Appiah, Ying Zhang, Uchechukwu Nwoke, Stephanie O Klopfer, Karen Eves, Kathleen Squires, Todd Correll, Michelle C Fox, M. Pisculli   +19 more
semanticscholar   +1 more source

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

The Lancet, 2019
BACKGROUND Effective two-drug regimens could decrease long-term drug exposure and toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy and safety of a two-drug regimen compared with a three-drug regimen for the ...
P. Cahn, J. S. Madero, J. Arribas, A. Antinori, Roberto Ortiz, A. Clarke, C. Hung, J. Rockstroh, P. Girard, Jörg Sievers, C. Man, A. Currie, M. Underwood, A. Tenorio, K. Pappa, B. Wynne, Anna Fettiplace, M. Gartland, M. Aboud, Kimberly Smith   +19 more
semanticscholar   +1 more source

Changes in Quality of Sleep, Mood, and Other Neuropsychiatric Symptoms After Switching Dolutegravir/Lamivudine/Abacavir to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in a Randomized Study of People With Human Immunodeficiency Virus With Poor Sleep Quality: GESIDA 10418

Open Forum Infectious Diseases, 2022
Background Although switching antiretroviral therapy (ART) in people with human immunodeficiency virus experiencing insomnia due to dolutegravir-related neurotoxicity is well founded upon evidence, there is a lack of proof in regard to the outcome of ...
Alfonso Cabello-Úbeda, A. Baeza, Jesús Troya García, S. de la Fuente Moral, M. N. Mena, A. P. Martínez, R. Micán, M. Górgolas, Guillermo Cuevas Tascón, A. D. de Santiago, José Sanz Morerno, D. R. Crestelo, C. B. Arenzana, José Ignacio Bernardino Serna, M. Almirón, J. Cano, H. Esteban, I. Pérez-Valero   +17 more
semanticscholar   +1 more source

HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women.

Journal of the American Medical Association (JAMA)
Importance Emtricitabine and tenofovir disoproxil fumarate (F/TDF) for HIV preexposure prophylaxis (PrEP) is highly effective in cisgender men who have sex with men (MSM) when adherence is high (>4 doses/week). Real-world effectiveness and adherence with
J. Marrazzo, Li Tao, Marissa Becker, Ashley A Leech, Allan W. Taylor, Faith Ussery, Michael Kiragu, S. Reza-Paul, Janet Myers, Linda-Gail Bekker, Juan Yang, Christoph C Carter, Melanie de Boer, M. Das, Jared M. Baeten, C. Celum   +15 more
semanticscholar   +1 more source

Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials.

The Lancet HIV, 2020
BACKGROUND In the primary week-48 analyses of two phase 3 studies, coformulated bictegravir, emtricitabine, and tenofovir alafenamide was non-inferior to a dolutegravir-containing regimen in treatment-naive people with HIV.
C. Orkin, E. Dejesus, P. Sax, J. Arribas, Samir K. Gupta, C. Martorell, J. L. Stephens, H. Stellbrink, D. Wohl, F. Maggiolo, M. Thompson, D. Podzamczer, D. Hagins, J. Flamm, C. Brinson, A. Clarke, Hailin Huang, Rima K. Acosta, D. Brainard, Sean E. Collins, Hal Martin   +20 more
semanticscholar   +1 more source

HPV42 – a human papillomavirus classified as a low‐risk type with oncogenic potential

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Human papillomavirus (HPV) type 42 is a rare HPV type currently classified as “low‐risk” and belongs to the alpha genus. It has primarily been detected in benign vulvar papillomas and is predominantly associated with benign lesions such as anogenital warts.
Sven Niklas Burmann, Ulrike Wieland, Steffi Silling, Frank Oellig, David Chromy, Julia Hyun, Thilo Gambichler, Alexander Kreuter   +7 more
wiley   +1 more source

Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy

AIDS (London)
Objective: To evaluate the efficacy and safety of 96 weeks of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) treatment in participants switching from dolutegravir (DTG)-based therapy.
C. Orkin, A. Antinori, Jürgen K. Rockstroh, Santiago Moreno-Guillén, C. Martorell, J. Molina, Adriano Lazzarin, F. Maggiolo, Y. Yazdanpanah, Kristen Andreatta, Hailin Huang, J. Hindman, Hal Martin, A. Pozniak   +13 more
semanticscholar   +1 more source

Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug–drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis

Journal of Antimicrobial Chemotherapy, 2022
Objectives Potential interactions between feminizing hormone therapy (FHT) and pre-exposure prophylaxis (PrEP) may be a barrier to PrEP use among transgender women (TGW). We aimed to assess the impact of FHT on PrEP plasma pharmacokinetics (PK) among TGW.
V. B. Cattani, E. Jalil, L. Eksterman, T. Torres, S. W. Cardoso, C. Castro, Laylla Monteiro, Erin C. Wilson, Lane R. Bushman, P. Anderson, V. Veloso, B. Grinsztejn, R. Estrela, Isabele Daniel M McMahon Desirée José Roberto Josias Toni Moura Waite Vieira Granjeiro Freitas Santos Fernan, I. Moura, D. M. M. Waite, D. Vieira, José Granjeiro, Josias Freitas, Toni Santos, N. Fernandes, Sandro C Nazer, Luana M S Marins, V. R. T. Ribeiro, Robson P. N. Silva, G. G. Costa, A. Vieira, Renata A Bastos, Aline Alves, Tania Krstic, A. C. Ferreira, M. Derrico, Luciana Kamel, C. Jalil, Eduardo Carvalheira Netto, M. D. G. de Sousa, Pedrosa Leite, Kim Geraldo Mattos, Jessica B. Felix, Tamires Vilela Baião, Gisele Hottz, Natália Gomes Maia, Tamiris Paixão da Silva, Michelle Ramos, Porto Tiago   +44 more
semanticscholar   +1 more source